Колоректальний рак
Детермінований перегляд YAML-сутності з джерельної бази. Клінічний авторитет лишається за вказаними source ID та статусом клінічного sign-off.
| ID | DIS-CRC |
|---|---|
| Тип | Хвороба |
| Синоніми | Bowel cancerColon cancer + Rectal cancerColorectal carcinomaКолоректальний рак |
| Статус | переглянуто 2026-04-26 | очікує клінічного підпису |
| Хвороби | Не вказано |
| Джерела | SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Інформаційна підтримка. Усі рекомендації має перевірити кваліфікований онколог. Технічні перевірки не є клінічною валідацією чи схваленням лікування.
| icd_o_3_morphology | 8140/3 |
|---|---|
| icd_o_3_topography | ["C18", "C19", "C20"] |
| icd_10 | C18-C20 |
| who_classification | WHO Digestive System Tumours 5th ed (2019): Adenocarcinoma of the colon and rectum |
Нотатки
Об'єднана нозологія, що охоплює рак ободової та прямої кишки. Більшість рішень щодо системної терапії для обох локалізацій спільні (FOLFOX/CAPOX у ад'ювантному режимі; FOLFIRINOX, FOLFOX + бевацизумаб / цетуксимаб / паніт- у метастатичному; пембролізумаб у першій лінії при MSI-H), однак для прямої кишки додатково виникають рішення щодо неоад'ювантної хіміопроменевої терапії та TNT, які поточна схема не може коректно виразити (див. PROPOSAL §17). Наразі специфічна для прямої кишки неоад'ювантна логіка документована у вільному тексті полів Indication notes; повне впорядкування секвенування очікує ратифікації пропозиції. Обов'язкові біомаркери відповідно до NCCN colon v4.2025 §pretreatment для будь-якої III-IV стадії: MSI / dMMR (визначальний для лікування при MSI-H), розширений RAS (KRAS екзони 2-4 + NRAS екзони 2-4), BRAF V600E, HER2 (рідкісний, але актиабельний у RAS-WT).
Де використовується
Algorithms
ALGO-AMSTERDAM-II-LYNCH- ALGO-AMSTERDAM-II-LYNCHALGO-CARRIER-CASCADE-LYNCH- ALGO-CARRIER-CASCADE-LYNCHALGO-CASCADE-FAMILY-TESTING- ALGO-CASCADE-FAMILY-TESTINGALGO-CLASSIC-FAP-CRITERIA- ALGO-CLASSIC-FAP-CRITERIAALGO-COWDEN-CARRIER-SURVEILLANCE- ALGO-COWDEN-CARRIER-SURVEILLANCEALGO-CRC-ADJUVANT- ALGO-CRC-ADJUVANTALGO-CRC-METASTATIC-1L- ALGO-CRC-METASTATIC-1LALGO-CRC-METASTATIC-2L- ALGO-CRC-METASTATIC-2LALGO-CRC-METASTATIC-3L- ALGO-CRC-METASTATIC-3LALGO-INTEGRATED-RISK-FROM-MULTIPLE-RFS- ALGO-INTEGRATED-RISK-FROM-MULTIPLE-RFSALGO-MMRPRO- ALGO-MMRPROALGO-MULTI-SYNDROME-PEDIGREE-TRIAGE- ALGO-MULTI-SYNDROME-PEDIGREE-TRIAGEALGO-PEUTZ-JEGHERS-CARRIER-SURVEILLANCE- ALGO-PEUTZ-JEGHERS-CARRIER-SURVEILLANCEALGO-PREMM5-LYNCH- ALGO-PREMM5-LYNCHALGO-PREVENTION-RISK-TRIAGE-OVERVIEW- ALGO-PREVENTION-RISK-TRIAGE-OVERVIEWALGO-RECTAL-LOCALLY-ADVANCED-TNT- ALGO-RECTAL-LOCALLY-ADVANCED-TNTALGO-REVISED-BETHESDA-LYNCH- ALGO-REVISED-BETHESDA-LYNCH
Handbook Chapters
HB-CRC-METASTATIC-1L- Metastatic colorectal cancer: first-line biomarker reasoning
Procedures
PROC-GENETIC-COUNSELING-PRE-TEST- Pre-test genetic counseling encounter for germline cancer-susceptibility testingPROC-PROPHYLACTIC-COLECTOMY-FAP- Prophylactic total/subtotal colectomy for classic FAPPROC-PROPHYLACTIC-HYSTERECTOMY-LYNCH- Risk-reducing hysterectomy with or without BSO in Lynch syndrome carriersSUR-TME-PROCTECTOMY- Proctectomy with total mesorectal excision (TME)
Questionnaires
QUEST-CRC-1L-STUB- Colorectal carcinoma — first line
Sources
SRC-BEAUGERIE-CESAME-2013- Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous...SRC-BISGAARD-FAP-2006- Familial adenomatous polyposis (FAP) — genotype correlation to FAP phenotype with osteoma...SRC-CAIRO3-SIMKENS-2015- Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (...SRC-CAPP2-LYNCH-ASPIRIN-BURN-2011- Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer (L...SRC-CHEN-MMRPRO-2006- Prediction of germline mutations and cancer risk in the Lynch syndrome (MMRpro)SRC-CLEARY-BLM-2003- Heterozygosity for the BLM(Ash) mutation and cancer riskSRC-CPP-CALCIUM-COLORECTAL-1999- Calcium supplements for the prevention of colorectal adenomas (Calcium Polyp Prevention S...SRC-ESMO-COLON-2024- ESMO CRC Clinical Practice GuidelineSRC-IDEA-GROTHEY-2018- Duration of Adjuvant Chemotherapy for Stage III Colon CancerSRC-MOSAIC-ANDRE-2004- Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon CancerSRC-NCCN-COLON-2025- NCCN Colon / Rectal CancerSRC-PACES-EFLORNITHINE-SULINDAC-2008- Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas...SRC-PRODIGE-23-CONROY-2021- Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients...SRC-RAPIDO-BAHADOER-2021- Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME)...SRC-TABORI-CMMRD-2017- Clinical Management and Tumor Surveillance Recommendations of Inherited Mismatch Repair D...SRC-TRIBE-LOUPAKIS-2014- FOLFOXIRI plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Treatment of Met...SRC-TRIBE2-CREMOLINI-2020- FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of pat...SRC-UMAR-BETHESDA-2004- Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome...SRC-VITAL-VITAMIN-D-OMEGA3-2019- Vitamin D supplements and prevention of cancer and cardiovascular disease (VITAL — Vitami...SRC-WIMMER-CMMRD-2014- Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions o...
Клінічна застосовність
BMA-APC-CRC- APC somatic loss-of-function mutations occur in ~80% of sporadic colorectal carcinomas (C...BMA-AXIN2-GERMLINE-CRC-OLIGODONTIA- AXIN2 germline pathogenic variants cause a Lynch-like attenuated polyposis + oligodontia...BMA-BLM-GERMLINE-BLOOM-BROAD- BLM germline biallelic pathogenic variants cause Bloom syndrome — autosomal-recessive dis...BMA-BRAF-V600E-CRC- BRAF V600E in metastatic CRC: encorafenib + cetuximab (with or without binimetinib) impro...BMA-CFDNA-MCED-MULTI-CANCER-SCREENING- Plasma cell-free DNA methylation classifiers (Galleri-style multi-cancer early detection...BMA-CTDNA-MRD-POST-TREATMENT-CRC- Post-resection ctDNA-MRD positivity in stage II/III colorectal cancer identifies patients...BMA-EPCAM-GERMLINE-CRC- EPCAM germline deletion (3' end) silences downstream MSH2 by promoter hypermethylation →...BMA-FBXW7-CRC- FBXW7 loss-of-function mutations occur in ~10–15% of CRC and result in stabilization of m...BMA-HER2-AMP-CRC- HER2-amplified metastatic colorectal cancer (~3-5% in RAS/BRAF-WT population): tucatinib...BMA-KRAS-A146T-CRC- KRAS A146T — rare, anti-EGFR contraindication marker. No targeted therapy.BMA-KRAS-EXON3-CRC- KRAS exon 3 codon 59/61 in mCRC — extended-RAS WT criterion fails; anti-EGFR (cetuximab/p...BMA-KRAS-EXON4-CRC- KRAS exon 4 codon 117/146 in mCRC — extended-RAS WT criterion fails; anti-EGFR (cetuximab...BMA-KRAS-G12C-CRC- KRAS G12C in mCRC (~3-4%): single-agent KRASG12C inhibitors insufficient (intrinsic EGFR...BMA-KRAS-G12D-CRC- KRAS G12D in mCRC predicts anti-EGFR resistance. No approved targeted therapy 2026; trial...BMA-KRAS-G12V-CRC- KRAS G12V in mCRC — anti-EGFR contraindication marker, no targeted therapy. Standard chem...BMA-KRAS-G12X-CRC- KRAS G12 (any) in mCRC — extended-RAS WT criterion fails; anti-EGFR (cetuximab/panitumuma...BMA-KRAS-G13D-CRC- KRAS G13D in mCRC — historical signal of partial cetuximab response (De Roock 2010) was n...BMA-KRAS-G13X-CRC- KRAS G13 (any non-G13C) in mCRC — extended-RAS WT criterion fails; anti-EGFR (cetuximab/p...BMA-KRAS-Q61-CRC- KRAS Q61 (any) in mCRC — extended-RAS WT criterion fails; anti-EGFR (cetuximab/panitumuma...BMA-MLH1-GERMLINE-CRC- MLH1 germline loss-of-function in crc produces dMMR/MSI-H phenotype. Pan-tumor MSI-H ICI...BMA-MLH1-SOMATIC-CRC- MLH1 somatic loss-of-function in crc produces dMMR/MSI-H phenotype. Pan-tumor MSI-H ICI e...BMA-MSH2-GERMLINE-CRC- MSH2 germline loss-of-function in crc produces dMMR/MSI-H phenotype. Pan-tumor MSI-H ICI...BMA-MSH2-SOMATIC-CRC- MSH2 somatic loss-of-function in crc produces dMMR/MSI-H phenotype. Pan-tumor MSI-H ICI e...BMA-MSH3-GERMLINE-POLYPOSIS-BIALLELIC- MSH3 germline biallelic pathogenic variants cause MSH3-associated polyposis (Adam et al....BMA-MSH6-GERMLINE-CRC- MSH6 germline loss-of-function in crc produces dMMR/MSI-H phenotype. Pan-tumor MSI-H ICI...BMA-MSH6-SOMATIC-CRC- MSH6 somatic loss-of-function in crc produces dMMR/MSI-H phenotype. Pan-tumor MSI-H ICI e...BMA-MSI-STATUS-CRC- MSI-H (microsatellite instability-high) CRC is the primary biomarker for first-line pembr...BMA-NRAS-G12-CRC- NRAS codon 12 mutation in mCRC — extended RAS WT criterion fails; anti-EGFR contraindicat...BMA-NRAS-G13-CRC- NRAS codon 13 in mCRC — anti-EGFR contraindicated.BMA-NRAS-Q61K-CRC- NRAS Q61K in mCRC — anti-EGFR contraindication.BMA-NRAS-Q61R-CRC- NRAS Q61R in mCRC — anti-EGFR (cetuximab/panitumumab) contraindication. Standard chemo ±...BMA-NTHL1-GERMLINE-NAP-BIALLELIC- NTHL1 germline biallelic (homozygous or compound heterozygous) pathogenic variants cause...BMA-NTRK-FUSION-CRC- NTRK fusion in CRC is rare (~0.1-0.3%) but enriched in MSI-H / Lynch syndrome CRC (~5-10%...BMA-PMS2-GERMLINE-CRC- PMS2 germline loss-of-function in crc produces dMMR/MSI-H phenotype. Pan-tumor MSI-H ICI...BMA-PMS2-SOMATIC-CRC- PMS2 somatic loss-of-function in crc produces dMMR/MSI-H phenotype. Pan-tumor MSI-H ICI e...BMA-POLD1-GERMLINE-POLYMERASE-PROOFREADING- POLD1 germline pathogenic variants in the exonuclease (proofreading) domain cause PPAP —...BMA-POLE-GERMLINE-POLYMERASE-PROOFREADING- POLE germline pathogenic variants in the exonuclease (proofreading) domain cause polymera...BMA-TP53-MUT-CRC- TP53 mutation in CRC — common, adverse prognostic; not directly targeted. Per usual algor...
Показання
IND-BLM-CARRIER-OBSERVATION- IND-BLM-CARRIER-OBSERVATIONIND-BLM-CARRIER-SURVEILLANCE- IND-BLM-CARRIER-SURVEILLANCEIND-CASCADE-FAP-FDR-POSITIVE-SURVEILLANCE- IND-CASCADE-FAP-FDR-POSITIVE-SURVEILLANCEIND-CASCADE-FAP-FDR-POSITIVE-TESTING- IND-CASCADE-FAP-FDR-POSITIVE-TESTINGIND-CASCADE-LYNCH-FDR-POSITIVE-SURVEILLANCE- IND-CASCADE-LYNCH-FDR-POSITIVE-SURVEILLANCEIND-CASCADE-LYNCH-FDR-POSITIVE-TESTING- IND-CASCADE-LYNCH-FDR-POSITIVE-TESTINGIND-CMMRD-CARRIER-PREVENTION-OBSERVATION- IND-CMMRD-CARRIER-PREVENTION-OBSERVATIONIND-CMMRD-CARRIER-PREVENTION-SURVEILLANCE- IND-CMMRD-CARRIER-PREVENTION-SURVEILLANCEIND-CRC-3L-FRUQUINTINIB- IND-CRC-3L-FRUQUINTINIBIND-CRC-ADJUVANT-STAGE2-HIGHRISK-FOLFOX- IND-CRC-ADJUVANT-STAGE2-HIGHRISK-FOLFOXIND-CRC-ADJUVANT-STAGE3-CAPOX- IND-CRC-ADJUVANT-STAGE3-CAPOXIND-CRC-ADJUVANT-STAGE3-FOLFOX- IND-CRC-ADJUVANT-STAGE3-FOLFOXIND-CRC-METASTATIC-1L-FOLFOX-BEV- IND-CRC-METASTATIC-1L-FOLFOX-BEVIND-CRC-METASTATIC-1L-FOLFOXIRI-BEV- IND-CRC-METASTATIC-1L-FOLFOXIRI-BEVIND-CRC-METASTATIC-1L-MSI-H-PEMBRO- IND-CRC-METASTATIC-1L-MSI-H-PEMBROIND-CRC-METASTATIC-1L-RAS-WT-LEFT- IND-CRC-METASTATIC-1L-RAS-WT-LEFTIND-CRC-METASTATIC-2L-BRAF-BEACON- IND-CRC-METASTATIC-2L-BRAF-BEACONIND-CRC-METASTATIC-2L-EGFRI-RECHALLENGE- IND-CRC-METASTATIC-2L-EGFRI-RECHALLENGEIND-CRC-METASTATIC-2L-FOLFIRI-BEV- IND-CRC-METASTATIC-2L-FOLFIRI-BEVIND-CRC-METASTATIC-2L-HER2-AMP-T-DXD- IND-CRC-METASTATIC-2L-HER2-AMP-T-DXDIND-CRC-METASTATIC-2L-HER2-AMP-TUCATINIB- IND-CRC-METASTATIC-2L-HER2-AMP-TUCATINIBIND-CRC-METASTATIC-2L-KRAS-G12C-SOTORASIB-CETUXIMAB- IND-CRC-METASTATIC-2L-KRAS-G12C-SOTORASIB-CETUXIMABIND-CRC-METASTATIC-2L-MSI-H-PEMBRO- IND-CRC-METASTATIC-2L-MSI-H-PEMBROIND-CRC-METASTATIC-3L-RECHALLENGE-EGFRI- IND-CRC-METASTATIC-3L-RECHALLENGE-EGFRIIND-CRC-METASTATIC-3L-REGORAFENIB- IND-CRC-METASTATIC-3L-REGORAFENIBIND-CRC-METASTATIC-3L-TAS102-BEV- IND-CRC-METASTATIC-3L-TAS102-BEVIND-CRC-METASTATIC-3L-TRIFLURIDINE-TIPIRACIL-MONO- IND-CRC-METASTATIC-3L-TRIFLURIDINE-TIPIRACIL-MONOIND-CRC-METASTATIC-MAINT-FOLFIRI-BEV- IND-CRC-METASTATIC-MAINT-FOLFIRI-BEVIND-CRC-OLIGOMET-LIVER-LIMITED- IND-CRC-OLIGOMET-LIVER-LIMITEDIND-CRC-PERFORMANCE-STATUS-3- IND-CRC-PERFORMANCE-STATUS-3IND-CRC-RENAL-FAILURE-MOD-FOLFOX- IND-CRC-RENAL-FAILURE-MOD-FOLFOXIND-CROHN-SPECIFIC-CANCER-PREVENTION-OBSERVATION- IND-CROHN-SPECIFIC-CANCER-PREVENTION-OBSERVATIONIND-CROHN-SPECIFIC-CANCER-PREVENTION-VIGILANCE- IND-CROHN-SPECIFIC-CANCER-PREVENTION-VIGILANCEIND-CRONKHITE-CANADA-OBSERVATION- IND-CRONKHITE-CANADA-OBSERVATIONIND-CRONKHITE-CANADA-SURVEILLANCE- IND-CRONKHITE-CANADA-SURVEILLANCEIND-FAP-CARRIER-INTENSIFIED- IND-FAP-CARRIER-INTENSIFIEDIND-FAP-CARRIER-SURVEILLANCE- IND-FAP-CARRIER-SURVEILLANCEIND-FAP-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCE- IND-FAP-SUSPICION-PREVENTION-ENHANCED-SURVEILLANCEIND-FAP-SUSPICION-PREVENTION-GENETIC-COUNSELING- IND-FAP-SUSPICION-PREVENTION-GENETIC-COUNSELINGIND-IBD-CRC-PREVENTION-CHROMOENDOSCOPY- IND-IBD-CRC-PREVENTION-CHROMOENDOSCOPY- ... 35 ще
Тривожна ознака
RF-ACTIVE-AUTOIMMUNE-DISEASE-ICI-RISK- Patient with active or incompletely controlled pre-existing autoimmune or inflammatory di...RF-BLM-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in the BLM gene — Bloom syndrom...RF-CASCADE-FAP-FDR-POSITIVE- A first-degree relative of the patient (parent, sibling, or child) has a documented posit...RF-CASCADE-LYNCH-FDR-POSITIVE- A first-degree relative of the patient (parent, sibling, or child) has a documented posit...RF-CHEK2-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic monoallelic variant in CHEK2. Most comm...RF-CHEK2-FAMILY-HISTORY-SUSPICION- Family pedigree pattern suggestive of germline CHEK2 heterozygous carrier state in an asy...RF-CHRONIC-IBD-CROHNS-SPECIFIC-PREVENTION- Crohn's disease (CD) with specific features that elevate cancer risk beyond the broader R...RF-CHRONIC-SEVERE-OBESITY-BMI40-PREVENTION- Severe obesity — BMI ≥40 kg/m² (WHO class III obesity), distinct from the broader RF-LIFE...RF-CHRONIC-T2DM-CANCER-RISK-PREVENTION- Established type-2 diabetes mellitus (HbA1c ≥6.5% on two occasions, or established T2DM d...RF-CMMRD-CONFIRMED-CARRIER- Confirmed biallelic germline pathogenic / likely-pathogenic variants in a mismatch repair...RF-COWDEN-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in the PTEN gene (Cowden syndro...RF-COWDEN-FAMILY-HISTORY-SUSPICION- Family pedigree suggestive of Cowden syndrome / PTEN hamartoma tumor syndrome (PHTS): any...RF-CRC-BRAF-V600E-POOR-PROGNOSIS- BRAF V600E mutation in mCRC: ~8-10% prevalence, poor prognosis (median OS halved vs BRAF-...RF-CRC-EMERGENCY-OBSTRUCTION-PERFORATION- Surgical emergency in CRC: complete bowel obstruction (closed-loop or large-bowel obstruc...RF-CRC-FRAILTY-AGE- Frailty/age profile precluding doublet-intensive or triplet chemo: ECOG ≥3, OR (age ≥80 +...RF-CRC-HER2-AMP-ACTIONABLE- HER2 amplification in metastatic colorectal cancer — IHC 3+ OR (IHC 2+ AND ISH amplified,...RF-CRC-INFECTION-SCREENING- Infection-screening gate before mCRC systemic therapy: HBsAg+ / anti-HBc+ (HBV reactivati...RF-CRC-MSI-H-ACTIONABILITY- MSI-high / dMMR mCRC — treatment-defining biomarker. KEYNOTE-177 established pembrolizuma...RF-CRC-OLIGOMET-LIVER-DEFINITION- Liver-limited oligometastatic colorectal cancer (CRLM, colorectal liver metastases) — a d...RF-CRC-RAS-MUTANT- Metastatic colorectal cancer with KRAS or NRAS hotspot mutation (KRAS exon 2 codons 12/13...RF-CRC-RAS-WT- Metastatic colorectal cancer with RAS wild-type status: KRAS exon 2 (codons 12, 13), exon...RF-CRC-TRANSFORMATION-PROGRESSION- Rapid progression in CRC: relapse within ≤6 months of completing adjuvant chemo (oxalipla...RF-CRONKHITE-CANADA-CONFIRMED- Cronkhite-Canada syndrome — acquired non-Mendelian polyposis- ectodermal syndrome. Rare (...RF-FAP-CONFIRMED-CARRIER- Patient has a confirmed germline APC pathogenic variant. Mandates structured colorectal +...RF-FAP-FAMILY-HISTORY-SUSPICION- Family pedigree suggestive of Familial Adenomatous Polyposis (FAP) or the attenuated FAP...RF-IBD-CRC-PREVENTION- Long-standing inflammatory bowel disease (IBD) with colonic involvement — either ulcerati...RF-JPS-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in SMAD4 or BMPR1A — Juvenile P...RF-LIFESTYLE-ALCOHOL-CANCER-PREVENTION- Heavy alcohol consumption — defined as >14 drinks/week (women) or >21 drinks/week (men) p...RF-LIFESTYLE-HIGH-RED-MEAT-CRC-PREVENTION- Habitual high red-meat consumption (≥500 g/week of cooked unprocessed red meat — beef, la...RF-LIFESTYLE-LOW-CALCIUM-VIT-D-CRC-PREVENTION- Combined low dietary calcium intake (<800 mg/day; IOM RDA 1000-1200 mg/day age-dependent)...RF-LIFESTYLE-LOW-FIBER-CRC-PREVENTION- Habitual low dietary fibre intake (<15 g/day; WCRF/AICR convincing- evidence threshold is...RF-LIFESTYLE-LOW-MEDITERRANEAN-DIET-PREVENTION- Low adherence to a Mediterranean dietary pattern (Trichopoulou Mediterranean Diet Score [...RF-LIFESTYLE-OBESITY-CANCER-PREVENTION- Obesity — BMI ≥30 kg/m² (per WHO definition) — OR class 2/3 obesity with BMI ≥35 / ≥40. I...RF-LIFESTYLE-PROCESSED-MEAT-PREVENTION- Regular processed-meat consumption ≥50 g/day per WCRF/IARC threshold. IARC Monograph 114...RF-LIFESTYLE-RED-MEAT-HIGH-INTAKE-PREVENTION- Habitual high consumption of UNPROCESSED red meat (beef, pork, lamb, veal, goat) — ≥500 g...RF-LIFESTYLE-SEDENTARY-PREVENTION- Low physical activity / sedentary lifestyle — defined as <150 min/week moderate-intensity...RF-LIFESTYLE-SUGARY-BEVERAGES-PREVENTION- High habitual intake of sugar-sweetened beverages (SSBs) — sodas, fruit drinks, sports dr...RF-LYNCH-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in a Lynch syndrome (MMR / EPCA...RF-LYNCH-FAMILY-HISTORY-SUSPICION- Family pedigree meeting criteria suggestive of hereditary nonpolyposis colorectal cancer...RF-OCC-FIREFIGHTER-PREVENTION- Documented historical occupational exposure as a career firefighter (≥10 years in active...- ... 7 ще
Хвороба
DIS-ADRENOCORTICAL-CARCINOMA- Adrenocortical carcinoma (ACC)